Dicot Pharma gets FDA clearance for first part of phase 2b study

▤ Summary

Dicot Pharma received FDA clearance for the first part of its phase 2b study. The item points to continued clinical development activity rather than a software product or corporate transaction. This kind of milestone matters to life sciences vendors because it can affect trial operations, data management, and compliance workflows. The available text does not include any additional operational details beyond the headline-level event.

▦ Linked Companies